Both companies’ boards of directors approved the $4.1 billion transaction.
Turning Point Therapeutics’s prize is repotrectinib, a drug targeting non-small cell lung cancer currently in its phase 1/2 clinical trials. Bristol Myers Squibb expects repotrectinib’s market debut in 2023.
“Today’s news builds upon our long legacy of pioneering next-generation medicines for patients with cancer,” Bristol Myers Squibb’s Chief Medical Officer Samit Hirawat, MD, said in a June 3 company news release. “With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients.”
The FDA granted Turning Point Therapeutics three breakthrough therapy designations for repotrectinib May 10.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
